This post was originally published on this site

An investigation on behalf of investors in Immunovant, Inc. (NASDAQ: IMVT) shares over potential wrongdoing at Immunovant, Inc. w

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Immunovant, Inc.

Investors who purchased shares of Immunovant, Inc. (NASDAQ: IMVT) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

The investigation by a law firm concerns whether certain Immunovant, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

New York based Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. On April 14, 2020, Immunovant, Inc. (NASDAQ: IMVT) announced the pricing of its underwritten public offering of 8,359,448 shares of its common stock at a price to the public of $14.50 per share. Immunovant, Inc estimated the the aggregate gross proceeds to Immunovant its initial public offering to be approximately $121.2 million, before deducting underwriting discounts and commissions and offering expenses.

On February 2, 2021, Immunovant, Inc. announced a “a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401,” a treatment for thyroid eye disease (“TED”). Immunovant, Inc. disclosed that it “has become aware of a physiological signal consisting of elevated total cholesterol and LDL levels in IMVT-1401-treated patients” and “[o]ut of an abundance of caution, the Company has decided to voluntarily pause dosing in ongoing clinical studies in both TED and in Warm Autoimmune Hemolytic Anemia, in order to inform patients, investigators, and regulators as well as to modify the monitoring program.”

Shares of Immunovant, Inc. (NASDAQ: IMVT) declined on February 2, 2021, to $22.50 per share.

Those who purchased shares of Immunovant, Inc. (NASDAQ: IMVT), have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.